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In healthy individuals, billions of cells die by apoptosis every day. Removal of the dead cells
by phagocytosis (a process called efferocytosis) must be efficient to prevent secondary
necrosis and the consequent release of pro-inflammatory cell contents that damages the
tissue environment and provokes autoimmunity. In addition, detection and removal of apop-
totic cells generally induces an anti-inflammatory response. As a consequence improper
clearance of apoptotic cells, being the result of either genetic anomalies and/or a per-
sistent disease state, contributes to the establishment and progression of a number of
human chronic inflammatory diseases such as autoimmune and neurological disorders,
inflammatory lung diseases, obesity, type 2 diabetes, or atherosclerosis. During the past
decade, our knowledge about the mechanism of efferocytosis has significantly increased,
providing therapeutic targets through which impaired phagocytosis of apoptotic cells and
the consequent inflammation could be influenced in these diseases.
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INTRODUCTION
Efficient execution of apoptotic cell death followed by efficient
clearance mediated by professional and by non-professional neigh-
boring phagocytes, is a key mechanism in maintaining tissue
homeostasis. Every day, billions of our cells die and get cleared
without initiating inflammation and an immune response (1).
Proper clearance of dead cells also contributes to the initiation
of tissue repair processes following injury (2–4). In addition, effi-
cient removal of apoptotic neutrophils is also a key event in the
resolution of inflammation (5).
Increasing evidence suggest that improper clearance of apop-
totic cells, being the result of either genetic anomalies and/or
a persistent disease state, contributes to the establishment and
progression of a number of human diseases via affects on the main-
tenance of tissue homeostasis, tissue repair, and inflammation (6).
Autoimmune disorders, in which both animal models and human
research indicate a strong relationship between improper clearance
and the development of the disease, represent the best character-
ized example of such diseases. The regulated nature of apoptotic
cell death normally prevents the leakage of the immunogenic
intracellular contents. If, however, these cells are not promptly
cleared, they undergo secondary necrosis leading to the release of
the intracellular antigens and DNA, which in the long-term pro-
voke an auto-inflammatory response (7). Thus, in most of the
knock out mice in which efferocytosis is impaired, systemic lupus
erythematosus (SLE) like autoimmunity develops (8–13). Human
SLE is also accompanied by improper efferocytosis (7), and can
develop also as a result of a genetic deficiency of the phagocytosis
process (13).
While in SLE improper clearance of apoptotic cells affects all the
tissues, in several chronic inflammatory respiratory diseases, such
as chronic obstructive pulmonary disease (COPD), cystic fibrosis,
and asthma, increased numbers of apoptotic cells are seen only in
the sputum and lung tissue (14). Though so far no evidence was
provided for a definite linkage between genetic anomalies affect-
ing efferocytosis and lung disease, inefficient apoptotic clearance
in the lung was detected in all these respiratory diseases (15).
Macrophages play a key role in the development of atheroscle-
rosis, and impaired clearance of apoptotic macrophages character-
izes the late plaques, in which uncleared apoptotic cells undergo
secondary necrosis leading to the formation of an unstable necrotic
core and the maintenance of inflammation (16). Impaired effe-
rocytosis, however, might also contribute to the development of
the disease, as knock out mice deficient in efferocytosis are prone
to develop atherosclerosis on LDL or ApoE null genetic back-
grounds (17–20). An excess of apoptotic cells was detected in a
numerous neurodegenerative diseases as well, such as Parkinson’s,
Alzheimer’s, and Huntington’s disease (21). Though the elevated
levels of apoptotic cells might also be the result of an increased neu-
ronal cell death, in these diseases loss of signaling by fractalkine
(an apoptotic cell “find me” signal) resulted in an increase in the
number of dying cells and worsening of the disease (22).
Interestingly, type 2 diabetes and obesity were also shown to
be associated with impaired phagocytosis of apoptotic β-cells
in the pancreas in autoimmune diabetes-prone rats (23) and
in ob/ob and db/db mice (24). The phenomenon seems to be
related to an enhanced saturated and/or decreased ω-3 fatty acid
composition of the plasma membrane, which leads to a decreased
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FIGURE 1 | Mechanism of apoptotic cell clearance. For initiating
phagocytosis apoptotic cells release “find me” signals for the phagocytes.
After finding the recognition of apoptotic cells by phagocyte receptors is
mediated by the display of “eat me” signals (e.g., PS and ACAMPs) and the
disappearance of the so-called “do not eat me” signals (e.g., CD31 and
CD47) on the apoptotic cell surface. Among others, these receptors
include the PS receptors (Tim4, stabilin-2, and BAI1) and receptors such as
MerTk, SCARF1, CD36, and integrin αvβ5 together with TG2 recognizing
apoptotic cells through bridging molecules (e.g., TSP-1, C1q, Gas6,
MFG-E8, and protein S). Binding of apoptotic cells to the phagocytic
receptors triggers two evolutionary conserved signaling pathways. MerTk,
BAI1, and αvβ3/5 receptors will activate the DOCK180/CrkII/ELMO
complex, while CD91/LPR1 and stabilin-2 will activate the adaptor protein
GULP. Both pathways converge on the small GTPase Rac, which initiates
actin rearrangement and phagocytosis. Following engulfment, apoptotic
cell derived lipids (oxysterols and fatty acids) trigger the lipid-sensing LXR
and PPAR receptors leading to enhanced retinoid production. Retinoid
receptors together with LXR and PPARs upregulate a number of
phagocytic receptors to further enhance the engulfing capacity of
macrophages under conditions when the rate of apoptosis is increased.
phosphatidylinositol 3-kinase activation during the uptake of
apoptotic cells (24).
MECHANISMS CONTRIBUTING TO EFFICIENT
PHAGOCYTOSIS OF APOPTOTIC CELLS
“FIND ME” AND “EAT ME” SIGNALS
To ensure effective removal, apoptotic cells recruit phagocytes
by releasing various soluble “find me” signals. These signals
include lysophosphatidylcholine (25), CX3CL1/fractalkine (26),
sphingosine-1-phosphate (27), the nucleotides ATP and UTP (28),
thrombospondin-1 (TSP-1) (29), and cleaved human tyrosyl-
tRNA synthetase (30). Upon arrival at the target cells, phago-
cytes must distinguish between apoptotic and viable cells. Apop-
totic cells display apoptotic cell-associated molecular patterns
(ACAMPs), which includes the appearance of “eat me” signals
on their cell surface (5). These can bind either directly or through
bridging molecules to receptors on phagocytes (Figure 1). Exter-
nalization of phosphatidylserine (PS) on the outer leaflet of the
cell membrane is the best characterized “eat me” signal dur-
ing apoptosis. The T-cell immunoglobulin- and mucin-domain-
containing molecule (Tim4), stabilin-2, and brain-specific angio-
genesis inhibitor 1 (BAI1) were reported to directly recognize PS
on dying cells (31–33), while other receptors such as Mer tyrosine
kinase (MerTk), scavenger receptor SCARF1, CD36, and integrin
αv/β3/β5 together with CD36 or tissue transglutaminase (TG2)
recognize apoptotic cells through bridging molecules. Gas6 and
protein S were found to facilitate apoptotic cell clearance by rec-
ognizing PS on apoptotic cells and MerTk receptor on phagocytes
(34, 35). TSP-1 and milk-fat globulin-E8 (MFG-E8) also bind to
PS and are recognized by the integrin αv/β3/CD36 or integrin
αv/β3/TG2 receptor complexes, respectively (36–38). The collectin
family member serum protein C1q also serves as a bridging mole-
cule by recognizing annexin A2 and A5 on the apoptotic cells (39)
and binding either SCARF1 scavenger receptor or the calreticulin
associated LRP1/CD91 receptor on phagocytes (39, 40). The LPS
coreceptor CD14 can also act as a tethering receptor for apoptotic
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cells, albeit its exact ligand remains unknown (41). Distinguishing
between apoptotic and viable cells is further ensured by the“do not
eat me” signals, which inhibit the uptake of living cells. CD47, acti-
vating SIRPα receptor, is one of these signals being expressed on
living cells but altered or diminished on apoptotic cell surface (42).
Additionally, homophilic interaction between CD31 on the target
cells and macrophages was shown to mediate cell detachment from
phagocytes, thus inhibiting phagocytosis of living cells (43).
ENGULFMENT AND INGESTION OF THE APOPTOTIC CORPSES
Uptake of the apoptotic cells requires the reorganization of
the actin filament network, which drives the movement of
the cell, formation of the phagocytic cup and the phagosome.
This process is regulated by the small GTPases RhoA, Cdc42,
and Rac. While RhoA activation was found to inhibit apop-
totic cell phagocytosis, Cdc42, and Rac were shown to enhance
it (44). Phagocytic receptors activate two evolutionary con-
served pathways both converging on the activation of Rac-1,
a small GTPase (45) (Figure 1). The first pathway is initi-
ated by MerTk or integrin αv/β5 receptors (46, 47), resulting
in association of the adaptor protein ELMO with the Rac GEF
DOCK180 forming a bipartite GEF (48). Recruitment of the
ELMO/DOCK180 complex to the cell membrane might require
the adaptor protein CrkII, but binding of ELMO to the car-
boxyl terminus of BAI1 also recruits DOCK180 to the phago-
cytic membranes (33). The second pathway activating the Rac
is initiated by LRP1 (CD91) (49) or by stabilin-2 receptors fol-
lowed by recruitment of the adaptor protein GULP (50). Fur-
ther steps, resulting in the activation of Rac are still unclear.
The newly formed phagosome must fuse with lysosomes to
degrade the dead cells. Recently, several autophagic genes were
described to participate in phagosome maturation (51, 52). Fol-
lowing phagolysosomal fusion, lysosomal enzymes degrade the
content of phagolysosomes. Lysosomal cathepsin protease CPL-
1 was found to be indispensable in the digestion of apoptotic cell
derived proteins (53), while lysosomal DNase II degrades the DNA
content (54).
REPROGRAMING OF PHAGOCYTES BY APOPTOTIC CELL CONTENT
Engulfment of apoptotic cells delivers excess materials to the
phagocytes. Some of these materials can be completely degraded,
while the excess of non-digestible cholesterol is removed via ATP-
binding cassette (ABC) transporters (Figure 1). Both PS (55) and
lipid-sensing nuclear receptors (56, 57) can upregulate the levels
of the ABCA1 transporter. The ingested macromolecules provide
the extra energy required for prolonged phagocytosis. However,
if too much energy is generated, engulfing cells upregulate the
mitochondrial uncoupling protein 2 (UCP2) and dissipate H+
gradient to reduce mitochondrial membrane potential (58). UCP2
also decreases reactive oxygen species formation.
To ensure efficient long-term phagocytosis, apoptotic cells
reprogram macrophages not only by altering their metabolism
but also by increasing the expression of a number of phago-
cytic receptors via activating peroxisome proliferator-activated
receptor (PPAR)δ/γ and liver X receptor (LXR)α/β receptors by
their lipid content (59–61). This process is partially mediated via
upregulation of endogenous retinoid synthesis (62, 63).
While the phagocytosis of a variety of pathogenic targets
normally triggers a pro-inflammatory response in macrophages,
ingestion of apoptotic cells by macrophages induces an anti-
inflammatory phenotype. The earliest anti-inflammatory activity
of the apoptotic cell is manifest as an immediate-early inhibi-
tion of macrophage pro-inflammatory cytokine gene transcrip-
tion and is exerted directly upon binding to the macrophage
(64). Subsequently, both nuclear receptors (65, 66) are activated
and soluble mediators are released from macrophages, which
act in a paracrine or autocrine fashion to amplify and sustain
the anti-inflammatory response (67, 68). During the resolution
of inflammation the reprogramed macrophages appear as pro-
resolving CD11blow macrophages (69) that express immunoreg-
ulatory 12/15-lipoxygenase (70) involved in the formation of
pro-resolving lipid mediators, termination of phagocytosis, and
emigration to lymphoid organs (69) required for the proper ter-
mination of the inflammatory program. This process is regulated
by the expression of a typical chemokine receptor D6 on the surface
of apoptotic neutrophils (71).
Since improper efferocytosis might contribute to both the
initiation and the maintenance of human diseases, enhancing
phagocytosis might provide a therapeutic possibility to influence
the progression of these diseases.
THERAPEUTIC POSSIBILITIES FOR ENHANCING
EFFEROCYTOSIS IN DISEASES IN WHICH CLEARANCE OF
APOPTOTIC CELLS IS IMPAIRED
AFFECTING RECOGNITION AND BINDING OF APOPTOTIC CELLS
If lack of sufficient MFG-E8 production leading to improper
efferocytosis participates in the pathomechanism of a disease,
providing MFG-E8 in recombinant protein form to the site of
acute inflammation might enhance the efficiency of efferocytosis.
Indeed, a decreased MFG-E8 expression was found in inflamed
colons during the acute phase of murine experimental colitis, and
intrarectal treatment with recombinant MFG-E8 ameliorated col-
itis by reducing inflammation and improving disease parameters
(72). Alternatively, both prolactin (73) and glucocorticoids (74)
can enhance MFG-E8 production providing a theoretical possibil-
ity for enhancing its expression in macrophages systematically.
MFG-E8 contains a PS binding domain, as well as an arginine–
glycine–aspartic acid (RGD) motif, which enables its binding to
integrins. Opsonization of the apoptotic cells and binding to inte-
grins on the surface of phagocytic cells, mediates the engulfment
of the dead cell. Based on this observation, an RGD–anxA5 was
designed, and it was shown that introduction of RGD transformed
the annexin A5, a molecule that binds to PS of apoptotic cells,
from an inhibitor into a stimulator of efferocytosis (75). While
recombinant MFG-E8 or the RGD–anxA5 could be utilized in
acute inflammation, long-term administration of MFG-E8 leads
to obesity, because it stimulates the fatty acid uptake of adipocytes
(76). It is an open question, whether chronic administration of
RGD–anxA5 would have the same side effects.
While MFG-E8 acts as a bridging molecule for integrins, Gas6,
and protein S are bridging molecules for MerTk. Thus in cases,
where MerTk plays a driving role in efferocytosis, such as car-
diac repair after myocardial infarction (4), provision of Gas6 or
protein S could similarly accelerate phagocytosis of apoptotic
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cells and tissue repair. Glucocorticoids enhance phagocytosis by
making efferocytosis MerTK dependent (77), thus combining
glucocorticoids and Gas6 or protein S might have a synergistic
effect.
Other bridging molecules, such as collectins, were also reported
to promote efferocytosis. Macrolide antibiotics, which have wide-
ranging anti-inflammatory effects, were found to enhance effe-
rocytosis by enhancing the expression of collectins (78). The
therapeutic potential of these drugs has already been recognized,
as they are successfully used in the treatment of COPD, cystic
fibrosis, or asthma (79).
TARGETING LIPID-SENSING NUCLEAR RECEPTORS WITH THE AIM OF
INCREASING THE EXPRESSION OF PHAGOCYTIC RECEPTORS OR THEIR
BRIDGING MOLECULES
Since nuclear receptor signaling is strongly associated with
enhanced efferocytosis and suppression of inflammation, glu-
cocorticoids, PPARγ, PPARδ, and LXR agonists or retinoids are
logical therapeutic targets in diseases in which efferocytosis is
impaired.
Glucocorticoids, the most widely used anti-inflammatory
drugs, were shown to enhance phagocytosis of apoptotic cells
by increasing the expression of the phospholipid binding protein
annexin A1 and its receptor ALXR (6, 80), as well as that of MerTK
(73, 81). Long-term effects of glucocorticoids were reported to be
mediated by PPARγ (82).
LXR agonists were shown to be effective in the treatment of
mouse models of atherosclerosis and inflammation. Thus, LXR
agonists [hypocholamide, T0901317, GW3965, or N,N -dimethyl-
3β-hydroxy-cholenamide (DMHCA)] lower the serum choles-
terol, and inhibit the development of atherosclerosis in murine
models of atherosclerosis (83), while GW3965 inhibits the expres-
sion of inflammatory mediators in cultured macrophages as well
as during in vivo inflammation (84). In addition, ligation of LXR
was shown to prevent the development of SLE like autoimmunity
in lpr mice (61) and decrease the disease severity in Alzheimer
disease (85).
While all LXR ligands are effective in enhancing efferocytosis,
T0901317, and GW3965 have been reported to increase plasma
and liver triglycerides in some mouse models (86). DMHCA, how-
ever, reduced atherosclerosis in apolipoprotein E-deficient mice
without inducing hypertriglyceridemia and liver steatosis (87).
Thus, developing new potent and effective LXR agonists with-
out the undesirable side effects may be beneficial for clinical usage
(88). In this aspect, it is worth noting that we found daidzein,
which is a plant-derived diphenolic isoflavone present in a num-
ber of plants and herbs (89) and has LXR and PPARγ activating
activity (90), to enhance efferocytosis efficiently. Daidzein, similar
to LXR agonists (91) induced the expression of TG2, as well as
decreased the mitochondrial membrane potential (92).
In addition to LXR agonists, PPARγ agonists were also shown
to reduce the neutrophil numbers in rodent models of acute
inflammation, such as asthma and COPD (93) and to increase
efferocytosis and therapeutic efficacy in a mouse model of
chronic granulomatosis (94). PPARγ and PPARδ agonists were also
shown to attenuate disease severity in experimental autoimmune
encephalomyelitis, a murine model of multiple sclerosis (95, 96).
Both RAR and RXR ligands promote efferocytosis, but their
effect is more pronounced if both receptors are activated (63).
The effect of in vivo all-trans retinoic acid (ATRA) treatment on
the development of lupus nephritis has already been tested in
both mouse models (97, 98) and humans (99). Lupus nephritis
is a major cause of morbidity and mortality in patients with SLE
(100). Long-term ATRA treatment in SLE-prone mice resulted in
longer survival, significant reduction of proteinuria, renal patho-
logical findings, and glomerular IgG deposits. In humans, it also
reduced proteinuria.
AFFECTING THE Rac-1/RhoA BALANCE
Since previous studies have shown that Rac activation is required,
while RhoA activation is inhibitory for effective clearance of apop-
totic cells (44), compounds that alter the Rac-1/RhoA balance, by
either increasing the level of active Rac-1 or decreasing the levels
and/or activity of RhoA/Rho kinase, would be potential candidates
for use in therapy. Among the anti-inflammatory drugs glucocorti-
coids were shown to alter the Rac-1/RhoA balance in macrophages
(101). Another molecule that was shown to affect the Rac-1/RhoA
balance is lipoxin A4, which enhances phagocytosis via a protein
kinase A-dependent manner (102). Though lipoxin A4 activates
both Rac-2 and RhoA, its positive effect on efferocytosis sug-
gests that the ultimate balance favors Rac activation. Lipoxins have
already been shown to reduce inflammation and tissue damage in
a variety of rodent models (103), and their levels are low in cys-
tic fibrosis patients (104). In addition, exposure to daidzein also
enhances Rac activity (92).
Statins are 3-hydroxy-3-methylglutaryl coenzyme A-reductase
inhibitors with potent anti-inflammatory effects, largely due to
their ability to inhibit the prenylation of Rho GTPases, including
Rac-1 and RhoA. Since proper membrane localization of these
proteins determines their function, statins inhibit the effective-
ness of G protein signaling. Lovastatin was shown to enhance
efferocytosis in vitro both in naïve murine lung and in alveolar
macrophages taken from COPD patients (105). It was demon-
strated that its effect is related to a disproportional deactivation
of the RhoGTPases favoring the activity of Rac-1, as well as to the
activation of PPARγ (106).
During inflammation oxidant-mediated activation of RhoA
and inhibition of efferocytosis might be reversed by antioxi-
dant treatment. Thus, in an LPS-induced lung injury model,
antioxidants enhanced efferocytosis and reduced inflammation by
inhibiting RhoA activation (107).
AFFECTING PHAGOSOME MATURATION
Increasing evidence suggests that autophagy and phagocytosis
processes are interactive and co-regulated. Thus, activation of
autophagy during salivary gland cell death in the Drosophila
requires the engulfment receptor Draper (108). In addition, asso-
ciation of LC3 with intracellular membranes described origi-
nally during autophagy was observed during phagocytosis as well
(109). In line with these observations, oridonin, an active diter-
penoid isolated from Rabdosia rubesens, was able to induce both
autophagy and enhance efferocytosis in the human macrophage-
like U937 cells. Moreover, enhancing autophagy by rapamycin
also enhanced phagocytosis of apoptotic cells by U937 cells
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(110). Thus, autophagy inducers might also promote effero-
cytosis. Though rapamycin and the so-called rapalogs are the
most effective clinically used inducers of autophagy, they have
severe immunosuppressive effects (111). That is why alterna-
tive, non-toxic autophagy inducers (such as rilmenidine or car-
bamazepine) are being characterized for their pharmacological
profile in suitable preclinical models (112, 113). In addition, other
non-toxic compounds, such as resveratrol and spermidine, are also
being evaluated for their potential to induce autophagy in vivo
(114, 115). These two latter compounds were shown to induce
autophagy by distinct pathways converging on the acetylproteome
(116). Resveratrol was suggested to mediate the cardioprotective
effect of red wine (117), while spermidine was shown to prolong
the life span of various organisms in an autophagy-dependent
manner (114). Though the effect of the latter compounds on
efferocytosis has not been tested yet, it is interesting to specu-
late whether enhanced efferocytosis contributes to their observed
beneficial in vivo effects.
ALTERING THE MEMBRANE LIPID COMPOSITION OF MACROPHAGES
Finally, studies on ob/ob and db/db mice indicate that in type 2 dia-
betes, obesity, or atherosclerosis impaired efferocytosis might be
related to altered membrane lipid compositions of macrophages.
In these cases, fish oil diet had a reversal effect (24). ω-3 fatty
acids provided by fish oil are known substrates for the biosyn-
thesis of pro-resolving mediators, such as resolvins, protectins,
and maresin which, similar to glucocorticoids or opsonization of
apoptotic cells by iC3b (69, 118), act as enhancers of efferocytosis
as well as promote the formation of CD11blow macrophages (119).
CONCLUDING REMARKS
Apoptotic cell death is an integral part of the cell turnover in
many tissues. If, however, dead cells are not properly cleared, their
content is released and induces tissue damage, as well as long-
term inflammation. It is increasingly recognized that improper
phagocytosis of apoptotic cells contributes to the establishment
and progression of a number of human chronic inflammatory
diseases. During the past decade, our knowledge about the mech-
anisms involved in efferocytosis increased significantly providing
potential pharmacological targets through which the efficiency of
apoptotic clearance could be increased. Since enhanced phago-
cytosis is coupled to an enhanced anti-inflammatory response,
targeting efferocytosis might provide an additional possibility
in the treatment of a numerous human chronic inflammatory
diseases.
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